217 related articles for article (PubMed ID: 27481935)
21. Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells.
Holler M; Grottke A; Mueck K; Manes J; Jücker M; Rodemann HP; Toulany M
PLoS One; 2016; 11(5):e0154745. PubMed ID: 27137757
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
Hampsch RA; Shee K; Bates D; Lewis LD; Désiré L; Leblond B; Demidenko E; Stefan K; Huang YH; Miller TW
Oncotarget; 2017 Mar; 8(13):21806-21817. PubMed ID: 28423521
[TBL] [Abstract][Full Text] [Related]
23. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
24. Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines.
Hausmann S; Brandt E; Köchel C; Einsele H; Bargou RC; Seggewiss-Bernhardt R; Stühmer T
PLoS One; 2015; 10(4):e0122689. PubMed ID: 25837824
[TBL] [Abstract][Full Text] [Related]
25. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
García-Martínez JM; Alessi DR
Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
[TBL] [Abstract][Full Text] [Related]
26. CXCL12-induced macropinocytosis modulates two distinct pathways to activate mTORC1 in macrophages.
Pacitto R; Gaeta I; Swanson JA; Yoshida S
J Leukoc Biol; 2017 Mar; 101(3):683-692. PubMed ID: 28250113
[TBL] [Abstract][Full Text] [Related]
27. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS
Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158
[TBL] [Abstract][Full Text] [Related]
28. Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress.
Thompson SM; Callstrom MR; Jondal DE; Butters KA; Knudsen BE; Anderson JL; Lien KR; Sutor SL; Lee JS; Thorgeirsson SS; Grande JP; Roberts LR; Woodrum DA
PLoS One; 2016; 11(9):e0162634. PubMed ID: 27611696
[TBL] [Abstract][Full Text] [Related]
29. Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition.
Dermit M; Casado P; Rajeeve V; Wilkes EH; Foxler DE; Campbell H; Critchlow S; Sharp TV; Gribben JG; Unwin R; Cutillas PR
Oncogene; 2017 May; 36(19):2762-2774. PubMed ID: 27991931
[TBL] [Abstract][Full Text] [Related]
30. ERK1/2-dependent activation of mTOR/mTORC1/p70S6K regulates thrombin-induced RPE cell proliferation.
Parrales A; López E; Lee-Rivera I; López-Colomé AM
Cell Signal; 2013 Apr; 25(4):829-38. PubMed ID: 23291002
[TBL] [Abstract][Full Text] [Related]
31. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
32. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ
Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769
[TBL] [Abstract][Full Text] [Related]
33. SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.
Gasser JA; Inuzuka H; Lau AW; Wei W; Beroukhim R; Toker A
Mol Cell; 2014 Nov; 56(4):595-607. PubMed ID: 25458846
[TBL] [Abstract][Full Text] [Related]
34. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.
Dienstmann R; Rodon J; Serra V; Tabernero J
Mol Cancer Ther; 2014 May; 13(5):1021-31. PubMed ID: 24748656
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
36. Cinderella finds her shoe: the first Vps34 inhibitor uncovers a new PI3K-AGC protein kinase connection.
Bilanges B; Vanhaesebroeck B
Biochem J; 2014 Dec; 464(2):e7-10. PubMed ID: 25395352
[TBL] [Abstract][Full Text] [Related]
37. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
38. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition.
Han EK; Leverson JD; McGonigal T; Shah OJ; Woods KW; Hunter T; Giranda VL; Luo Y
Oncogene; 2007 Aug; 26(38):5655-61. PubMed ID: 17334390
[TBL] [Abstract][Full Text] [Related]
39. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
[TBL] [Abstract][Full Text] [Related]
40. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
Musa F; Alard A; David-West G; Curtin JP; Blank SV; Schneider RJ
Mol Cancer Ther; 2016 Jul; 15(7):1557-67. PubMed ID: 27196780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
